Related references
Note: Only part of the references are listed.Neurovascular Unit: A critical role in ischemic stroke
Liyun Wang et al.
CNS NEUROSCIENCE & THERAPEUTICS (2021)
Thinking Outside the Ischemia Box: Advancements in the Use of Multiple Sclerosis Drugs in Ischemic Stroke
Athina-Maria Aloizou et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study A Randomized Clinical Trial
Ludwig Kappos et al.
JAMA NEUROLOGY (2021)
In vivo detection of teriflunomide-derived fluorine signal during neuroinflammation using fluorine MR spectroscopy
Christian Prinz et al.
THERANOSTICS (2021)
The action of TH17 cells on blood brain barrier in multiple sclerosis and experimental autoimmune encephalomyelitis
Rodica Balasa et al.
HUMAN IMMUNOLOGY (2020)
Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain
William M. Pardridge
FRONTIERS IN AGING NEUROSCIENCE (2020)
The blood-brain barrier in health and disease: Important unanswered questions
Caterina P. Profaci et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
Immuno-metabolic impact of the multiple sclerosis patients' sera on endothelial cells of the blood-brain barrier
M. H. Sheikh et al.
JOURNAL OF NEUROINFLAMMATION (2020)
Targeting and Crossing the Blood-Brain Barrier with Extracellular Vesicles
Julien Saint-Pol et al.
CELLS (2020)
Cladribine modifies functional properties of microglia
L. O. Jorgensen et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2020)
Blood-Brain Barrier: More Contributor to Disruption of Central Nervous System Homeostasis Than Victim in Neurological Disorders
Minjia Xiao et al.
FRONTIERS IN NEUROSCIENCE (2020)
Which is the best PML risk stratification strategy in natalizumab-treated patients affected by multiple sclerosis?
Carla Prezioso et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Approved and Emerging Disease Modifying Therapies on Neurodegeneration in Multiple Sclerosis
Madeline Bross et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Promising Nanotechnology Approaches in Treatment of Autoimmune Diseases of Central Nervous System
Maria Chountoulesi et al.
BRAIN SCIENCES (2020)
Natalizumab in acute ischemic stroke (ACTION II) A randomized, placebo-controlled trial
Mitchell S. V. Elkind et al.
NEUROLOGY (2020)
A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis
Gavin Giovannoni et al.
NEUROLOGY (2020)
Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab
C. L. Kemmerer et al.
PLOS ONE (2020)
Targeting nanoparticles to the brain by exploiting the blood-brain barrier impermeability to selectively label the brain endothelium
Daniel Gonzalez-Carter et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
The Involvement of Exosomes in Glioblastoma Development, Diagnosis, Prognosis, and Treatment
Adrian Balasa et al.
BRAIN SCIENCES (2020)
Dimethyl Fumarate and Its Esters: A Drug with Broad Clinical Utility?
Stephanie Kourakis et al.
PHARMACEUTICALS (2020)
The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review
Kottil Rammohan et al.
DRUGS (2020)
A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity
Hossam Kadry et al.
FLUIDS AND BARRIERS OF THE CNS (2020)
Pre-clinical and Clinical Implications of Inside-Out vs. Outside-In Paradigms in Multiple Sclerosis Etiopathogenesis
Haley E. Titus et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2020)
Siponimod: A Review in Secondary Progressive Multiple Sclerosis
Lesley J. Scott
CNS DRUGS (2020)
The direct deleterious effect of Th17 cells in the nervous system compartment in multiple sclerosis and experimental autoimmune encephalomyelitis: one possible link between neuroinflammation and neurodegeneration
Rodica Balasa et al.
REVISTA ROMANA DE MEDICINA DE LABORATOR (2020)
Oral Therapies for Multiple Sclerosis
Simon Faissner et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2019)
Silent progression in disease activity-free relapsing multiple sclerosis
Bruce A. C. Cree et al.
ANNALS OF NEUROLOGY (2019)
Applications of nanotechnology in drug delivery to the central nervous system
Majid Saeedi et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis
Sudhir Kumar Yadav et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2019)
MS-STAT2: A PHASE 3 TRIAL OF HIGH DOSE SIMVASTATIN IN SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
E. Williams et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2019)
Effect of dimethyl fumarate on lymphocytes in RRMS Implications for clinical practice
Devangi Mehta et al.
NEUROLOGY (2019)
Development and Cell Biology of the Blood-Brain Barrier
Urs H. Langen et al.
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, VOL 35 (2019)
Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes
Karl E. Carlstrom et al.
NATURE COMMUNICATIONS (2019)
Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis
Colm Elliott et al.
BRAIN (2019)
Progressive multiple sclerosis: from pathophysiology to therapeutic strategies
Simon Faissner et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
BLOOD-BRAIN BARRIER: FROM PHYSIOLOGY TO DISEASE AND BACK
Melanie D. Sweeney et al.
PHYSIOLOGICAL REVIEWS (2019)
Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study
Konrad Rejdak et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Claudin-5: gatekeeper of neurological function
Chris Greene et al.
FLUIDS AND BARRIERS OF THE CNS (2019)
Vascular pathology in multiple sclerosis: reframing pathogenesis around the blood-brain barrier
Jonathan I. Spencer et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2018)
Treatment response to dimethyl fumarate is characterized by disproportionate CD8+T cell reduction in MS
Vinzenz Fleischer et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study
Ludwig Kappos et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Treatment response to dimethyl fumarate is characterized by disproportionate CD8+T cell reduction in MS
Vinzenz Fleischer et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study
Ludwig Kappos et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Fingolimod inhibits brain atrophy and promotes brain-derived neurotrophic factor in an animal model of multiple sclerosis
Paul A. Smith et al.
JOURNAL OF NEUROIMMUNOLOGY (2018)
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Ludwig Kappos et al.
LANCET (2018)
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
Raja Kapoor et al.
LANCET NEUROLOGY (2018)
Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis
Elizabeth A. Mills et al.
FRONTIERS IN NEUROLOGY (2018)
The Matrix Metalloproteinases Panel in Multiple Sclerosis Patients Treated with Natalizumab: A Possible Answer to Natalizumab Non-Responders
Rodica Balasa et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2018)
Clinical and Serological Biomarkers of Treatment's Response in Multiple Sclerosis Patients Treated Continuously with Interferon beta-1b for More than a Decade
Laura Iulia Barcutean et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2018)
Blockade of MCAM/CD146 impedes CNS infiltration of T cells over the choroid plexus
Johanna Breuer et al.
JOURNAL OF NEUROINFLAMMATION (2018)
Gadolinium and Multiple Sclerosis: Vessels, Barriers of the Brain, and Glymphatics
C. Saade et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2018)
Fingolimod enhances the efficacy of delayed alteplase administration in acute ischemic stroke by promoting anterograde reperfusion and retrograde collateral flow
De-Cai Tian et al.
ANNALS OF NEUROLOGY (2018)
Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial
Jacob Elkins et al.
LANCET NEUROLOGY (2017)
Engineered Exosomes as Vehicles for Biologically Active Proteins
Ulrich Sterzenbach et al.
MOLECULAR THERAPY (2017)
New insights into the burden and costs of multiple sclerosis in Europe
Gisela Kobelt et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Laquinimod enhances central nervous system barrier functions
Fred Luehder et al.
NEUROBIOLOGY OF DISEASE (2017)
Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis
Burhan Z. Chaudhry et al.
NEUROTHERAPEUTICS (2017)
New insights into the burden and costs of multiple sclerosis in Europe
Gisela Kobelt et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Effects of fumarates on inflammatory human astrocyte responses and oligodendrocyte differentiation
Dylan A. Galloway et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2017)
Fibrin(ogen) and Neurodegeneration in the Progressive Multiple Sclerosis Cortex
Richard L. Yates et al.
ANNALS OF NEUROLOGY (2017)
CCR6+ Th cells in the cerebrospinal fluid of persons with multiple sclerosis are dominated by pathogenic non-classic Th1 cells and GM-CSF-only-secreting Th cells
S. M. Restorick et al.
BRAIN BEHAVIOR AND IMMUNITY (2017)
Dimethyl fumarate-induced lymphopenia in MS due to differential T-cell subset apoptosis
Mahtab Ghadiri et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)
Sphingosine 1-Phosphate Receptor Modulators and Drug Discovery
Soo-Jin Park et al.
BIOMOLECULES & THERAPEUTICS (2017)
Assessment of Interleukin-17A, Interleukin-10 and Transforming Growth Factor-Beta1 Serum Titers in Relapsing Remitting Multiple Sclerosis Patients Treated with Avonex, Possible Biomarkers for Treatment Response
Rodica Balasa et al.
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS (2017)
Molecular alterations of the blood-brain barrier under inflammatory conditions: The role of endothelial to mesenchymal transition
Claudio Derada Troletti et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2016)
Immune cell trafficking across the barriers of the central nervous system in multiple sclerosis and stroke
Melissa A. Lopes Pinheiro et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2016)
CSF, blood-brain barrier, and brain drug delivery
William M. Pardridge
EXPERT OPINION ON DRUG DELIVERY (2016)
Inflammation and Stroke: An Overview
Josef Anrather et al.
NEUROTHERAPEUTICS (2016)
Laquinimod in the treatment of multiple sclerosis: a review of the data so far
Jan Thoene et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2016)
Relapses in multiple sclerosis: Relationship to disability
Douglas S. Goodin et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2016)
Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS
Benedetta Parodi et al.
ACTA NEUROPATHOLOGICA (2015)
Permeability of the blood-brain barrier predicts conversion from optic neuritis to multiple sclerosis
Stig P. Cramer et al.
BRAIN (2015)
Combination of the Immune Modulator Fingolimod With Alteplase in Acute Ischemic Stroke A Pilot Trial
Zilong Zhu et al.
CIRCULATION (2015)
Statin Treatment in Multiple Sclerosis: A Systematic Review and Meta-Analysis
Gorm Pihl-Jensen et al.
CNS DRUGS (2015)
Dimethyl Fumarate Protects Neural Stem/Progenitor Cells and Neurons from Oxidative Damage through Nrf2-ERK1/2 MAPK Pathway
Qin Wang et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
Leukocyte integrins: Role in leukocyte recruitment and as therapeutic targets in inflammatory disease
Ioannis Mitroulis et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Transmembrane proteins of the tight junctions at the blood-brain barrier: Structural and functional aspects
Reiner F. Haseloff et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2015)
The Molecular Constituents of the Blood-Brain Barrier
Brian Wai Chow et al.
TRENDS IN NEUROSCIENCES (2015)
How leukocytes cross the vascular endothelium
Dietmar Vestweber
NATURE REVIEWS IMMUNOLOGY (2015)
Dimethyl fumarate inhibits integrin α4 expression in multiple sclerosis models
Yasuyuki Kihara et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2015)
Role of the Blood-Brain Barrier in Multiple Sclerosis
Genaro Gabriel Ortiz et al.
ARCHIVES OF MEDICAL RESEARCH (2014)
Glucocorticoids and endothelial cell barrier function
Ellaine Salvador et al.
CELL AND TISSUE RESEARCH (2014)
Cerebral lesions of multiple sclerosis: is gadolinium always irreplaceable in assessing lesion activity?
Constantina Andrada Treaba et al.
DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY (2014)
Rapid Remodeling of Tight Junctions during Paracellular Diapedesis in a Human Model of the Blood-Brain Barrier
Ryan C. Winger et al.
JOURNAL OF IMMUNOLOGY (2014)
Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage
Massimo Filippi et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)
Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial
Jeremy Chataway et al.
LANCET (2014)
Impact of an immune modulator fingolimod on acute ischemic stroke
Ying Fu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis
Valerie Jolivel et al.
BRAIN (2013)
Initial Immunopathogenesis of Multiple Sclerosis: Innate Immune Response
Norma Y. Hernandez-Pedro et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2013)
Modulation of Rho-Rock signaling pathway protects oligodendrocytes against cytokine toxicity via PPAR--dependent mechanism
Ajaib S. Paintlia et al.
GLIA (2013)
Fingolimod phosphate promotes the neuroprotective effects of microglia
Hiromi Noda et al.
JOURNAL OF NEUROIMMUNOLOGY (2013)
Fingolimod: Direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy
Aran Groves et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2013)
Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes
Ruben van Doorn et al.
ACTA NEUROPATHOLOGICA (2012)
Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination
Wolfgang Brueck et al.
ACTA NEUROPATHOLOGICA (2012)
Modulation of Autoimmune Demyelination by Laquinimod via Induction of Brain-Derived Neurotrophic Factor
Jan Thoene et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
T cells become licensed in the lung to enter the central nervous system
Francesca Odoardi et al.
NATURE (2012)
Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
Giancarlo Comi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Interferon beta for secondary progressive multiple sclerosis
Loredana La Mantia et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2012)
The anatomical and cellular basis of immune surveillance in the central nervous system
Richard M. Ransohoff et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Vascular Cell Adhesion Molecule-1 Expression and Signaling During Disease: Regulation by Reactive Oxygen Species and Antioxidants
Joan M. Cook-Mills et al.
ANTIOXIDANTS & REDOX SIGNALING (2011)
Central nervous system recruitment of effector memory CD8+ T lymphocytes during neuroinflammation is dependent on α4 integrin
Igal Ifergan et al.
BRAIN (2011)
Cladribine: Mode of Action and Implications for Treatment of Multiple Sclerosis
Thomas P. Leist et al.
CLINICAL NEUROPHARMACOLOGY (2011)
Fingolimod modulates microglial activation to augment markers of remyelination
Samuel J. Jackson et al.
JOURNAL OF NEUROINFLAMMATION (2011)
Vascular aspects of multiple sclerosis
Miguel D'haeseleer et al.
LANCET NEUROLOGY (2011)
Inflammatory Cortical Demyelination in Early Multiple Sclerosis
Claudia F. Lucchinetti et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
MULTIPLE SCLEROSIS IS NOT A DISEASE OF THE IMMUNE SYSTEM
Angelique P. Corthals
QUARTERLY REVIEW OF BIOLOGY (2011)
Impact of cladribine on soluble adhesion molecules in multiple sclerosis
K. Mitosek-Szewczyk et al.
ACTA NEUROLOGICA SCANDINAVICA (2010)
Evidence for a two-stage disability progression in multiple sclerosis
Emmanuelle Leray et al.
BRAIN (2010)
Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
Jerold Chun et al.
CLINICAL NEUROPHARMACOLOGY (2010)
The neurovascular unit in the setting of stroke
G. J. del Zoppo
JOURNAL OF INTERNAL MEDICINE (2010)
Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis
Christiane Wegner et al.
JOURNAL OF NEUROIMMUNOLOGY (2010)
Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1β, TNF-α and IL-6 in an in-vitro model of brain inflammation
Henrik Wilms et al.
JOURNAL OF NEUROINFLAMMATION (2010)
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
Gavin Giovannoni et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The relation between inflammation and neurodegeneration in multiple sclerosis brains
Josa M. Frischer et al.
BRAIN (2009)
Oxidative stress is increased in serum from Mexican patients with relapsing-remitting multiple sclerosis
Genaro Gabriel Ortiz et al.
DISEASE MARKERS (2009)
Mechanisms for transcellular diapedesis: probing and pathfinding by 'invadosome-like protrusions'
Christopher V. Carman
JOURNAL OF CELL SCIENCE (2009)
Cloning and characterization of the murine claudin-5 promoter
Malgorzata Burek et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2009)
C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE
Andrea Reboldi et al.
NATURE IMMUNOLOGY (2009)
Novel aspects in the regulation of the leukocyte adhesion cascade
Emmanouil Chavakis et al.
THROMBOSIS AND HAEMOSTASIS (2009)
FTY720 modulates human oligodendrocyte progenitor process extension and survival
Veronique E. Miron et al.
ANNALS OF NEUROLOGY (2008)
Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis
Simone Wuest et al.
JOURNAL OF IMMUNOLOGY (2008)
Central nervous system-directed effects of FTY720 (fingolimod)
Veronique E. Miron et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2008)
FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis
M. Mehling et al.
NEUROLOGY (2008)
Review: Mitochondria and disease progression in multiple sclerosis
D. Mahad et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2008)
Mechanism of action of glatiramer acetate in treatment of multiple sclerosis
Martin S. Weber et al.
NEUROTHERAPEUTICS (2007)
Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation
Hania Kebir et al.
NATURE MEDICINE (2007)
Persistent endothelial abnormalities and blood-brain barrier leak in primary and secondary progressive multiple sclerosis
S. Leech et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2007)
Essential roles of sphingosine 1-phosphate/S1P(1) receptor axis in the migration of neural stem cells toward a site of spinal cord injury
Atsushi Kimura et al.
STEM CELLS (2007)
The impact of interferon-β treatment on the blood-brain barrier
Joerg Kraus et al.
DRUG DISCOVERY TODAY (2006)
Immune surveillance of the human central nervous system (CNS): Different migration pathways of immune cells through the blood-brain barrier and blood-cerebrospinal fluid barrier in healthy persons
TO Kleine et al.
CYTOMETRY PART A (2006)
Identification of in vivo phosphorylation sites on human deoxycytidine kinase -: Role of Ser-74 in the control of enzyme activity
C Smal et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis
L Steinman et al.
TRENDS IN IMMUNOLOGY (2005)
The circumventricular organs participate in the immunopathogenesis of experimental autoimmune encephalomyelitis
Martina Schulz et al.
FLUIDS AND BARRIERS OF THE CNS (2005)
The mechanism of action of methylprednisolone in the treatment of multiple sclerosis
JS Sloka et al.
MULTIPLE SCLEROSIS JOURNAL (2005)
Occludin as direct target for glucocorticoid-induced improvement of blood-brain barrier properties in a murine in vitro system
C Förster et al.
JOURNAL OF PHYSIOLOGY-LONDON (2005)
Diapedesis of mononuclear cells across cerebral venules during experimental autoimmune encephalomyelitis leaves tight junctions intact
H Wolburg et al.
ACTA NEUROPATHOLOGICA (2005)
Interferon-β stabilizes barrier characteristics of brain endothelial cells in vitro
J Kraus et al.
ANNALS OF NEUROLOGY (2004)
FTY720: Sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function
V Brinkmann et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2004)
Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability
T Sanchez et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes
SD Sorensen et al.
MOLECULAR PHARMACOLOGY (2003)
The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease
S Youssef et al.
NATURE (2002)
Interferon-β counteracts inflammatory mediator-induced effects on brain endothelial cell tight junction molecules -: Implications for multiple sclerosis
PA Kuruganti et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2002)
Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue
LP Zou et al.
NEUROPHARMACOLOGY (2002)
Treatment with methylprednisolone in relapses of multiple sclerosis patients: immunological evidence of immediate and short-term but not long-lasting effects
EM Martinez-Caceres et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2002)
Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis
R Stanislaus et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2001)
High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes
VI Leussink et al.
ARCHIVES OF NEUROLOGY (2001)
Glucocorticoid receptor-mediated suppression of activator protein-1 activation and matrix metalloproteinase expression after spinal cord injury
J Xu et al.
JOURNAL OF NEUROSCIENCE (2001)
High-dose methylprednisolone reduces cytokine-induced adhesion molecules on human brain endothelium
M Gelati et al.
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2000)
Differential adhesion molecule requirements for immune surveillance and inflammatory recruitment
MD Carrithers et al.
BRAIN (2000)
Share Paper
